Therapy Areas: Devices
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
22 March 2019 - - US-based ophthalmic pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has started patient dosing in its Phase 2 clinical trial designed in accordance with the require...
GenePOC awarded US FDA clearance for GenePOC Strep A Test, reflecting its third approved test in the US
22 March 2019 - GenePOC Inc disclosed on Thursday the receipt of approval from the US FDA for the GenePOC Strep A assay to be used along with the revogene device.The Group A Streptococcus (GAS) infect...
Impulse Dynamics wins US FDA's approval for first-in-class Optimizer Smart System for treatment of heart failure
22 March 2019 - Heart failure treatment company Impulse Dynamics reported on Thursday the receipt of approval from the US Food and Drug Administration for its first-in-class Optimizer Smart System des...
Aura to Present Interim Phase 1b/2 Clinical Data for AU-011 at the International Society of Ocular Oncology 2019 Annual Meeting
21 March 2019 - - US-based Aura Biosciences, a specialist in the development of novel targeted therapies in ocular oncology, will present interim clinical data from its Phase 1b/2 clinical trial evalu...
Titan Medical provides update of final prospectus filing
20 March 2019 - Medical device company Titan Medical Inc (TSX:TMD) (NASDAQ:TMDI) said on Tuesday that it has filed a final short form prospectus in connection with the marketed offering of units at a ...
Soliton to file for US FDA approval of the RAP technology following clinical trials
20 March 2019 - Medical device company Soliton Inc (Nasdaq:SOLY) said on Tuesday that it has completed the human trials of its proprietary Rapid Acoustic Pulse (RAP) technology to accelerate tattoo fa...